Table 2 Association of GTSE1 mRNA expression with clinicopathological features in PCa.
From: GTSE1 promotes prostate cancer cell proliferation via the SP1/FOXM1 signaling pathway
GTSE1 mRNA expression | ||||
|---|---|---|---|---|
Characteristics | Total no. (%) | Low no. (%) | Hight no. (%) | P |
All cases | 257 (100.0) | 129 (50.2) | 128 (49.8) | – |
Age | 0.062 | |||
<65 | 90 (54.5) | 75 (45.5) | ||
≥65 | 39 (42.4) | 53 (57.6) | ||
PSA (ng/mL) | 0.098 | |||
<10 | 87 (52.4) | 79 (47.6) | ||
10–20 | 29 (54.7) | 24 (45.3) | ||
>20 | 13 (34.2) | 25 (65.8) | ||
Gleason score | <0.001 | |||
6 | 16 (84.2) | 3 (15.8) | ||
7 (3 + 4) | 50 (56.8) | 38 (43.2) | ||
7 (4 + 3) | 34 (61.8) | 21 (38.2) | ||
8–10 | 29 (30.5) | 66 (69.5) | ||
Pathological T stage | 0.011 | |||
T2 | 57 (62.0) | 35 (38.0) | ||
T3 | 70 (44.6) | 87 (55.4) | ||
T4 | 2 (25.0) | 6 (75.0) | ||
Pathological N stage | 0.006 | |||
N0 | 113 (54.3) | 95 (45.7) | ||
N1 | 16 (32.7) | 33 (67.3) | ||
